Pharmaceuticals India

India Lung Cancer Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Lung Cancer Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $688.8 Mn Placeholder estimate
Estimate 2025 $781.1 Mn 2% of the global market
Projected 2034 $2.42 Bn 210.1% Adds $1.64 Bn over 9 forecast years
CAGR 2025–2034 13.4% Faster than 63% of 180 Pharmaceuticals markets here
Key players 6 +1
  • India is 1.96% of the global market.
  • In APAC, the largest is China at $3.28 Bn.
  • Fastest growing: India (this report) at 13.4% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.64 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Lung Cancer Therapeutics Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $688.8 Mn — —
2025 (base) $781.1 Mn +$92.3 Mn —
2026 (forecast) $885.8 Mn +$104.7 Mn +13.4%
2027 (forecast) $1.00 Bn +$118.7 Mn +28.6%
2028 (forecast) $1.14 Bn +$134.6 Mn +45.8%
2029 (forecast) $1.29 Bn +$152.6 Mn +65.4%
2030 (forecast) $1.46 Bn +$173.1 Mn +87.5%
2031 (forecast) $1.66 Bn +$196.3 Mn +112.7%
2032 (forecast) $1.88 Bn +$222.6 Mn +141.2%
2033 (forecast) $2.14 Bn +$252.4 Mn +173.5%
2034 (forecast) $2.42 Bn +$286.2 Mn +210.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Lung Cancer Therapeutics Market Analysis at a glance
Market size, 2025$781.1 Mn placeholder estimate
Forecast, 2034$2.42 Bn placeholder estimate
Growth (CAGR), 2025–203413.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, type and end user (see all)
Key playersMerck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and 1 more (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
Active clinical trials69 in IndiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Lung Cancer Therapeutics Market Analysis Executive Summary

Lung cancer therapeutics include targeted drugs, immunotherapy, chemotherapy and antibody-drug conjugates for small-cell and non-small cell lung cancer.

Key segments of the lung Cancer Therapeutics market include drug class (Targeted Therapy, Immunotherapy and Chemotherapy) and type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer).

Bar chart: India Lung Cancer Therapeutics market size, 2024–2034, placeholder estimates. $688.8 Mn in 2024, $781.1 Mn in 2025 and $2.42 Bn in 2034, 13.4% CAGR.
India Lung Cancer Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Lung Cancer Therapeutics Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the lung Cancer Therapeutics market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the lung Cancer Therapeutics market, especially in low- and middle-income countries.

Competitive Landscape for Lung Cancer Therapeutics Market in India

The lung Cancer Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Lung Cancer Therapeutics Market in India

Lung Cancer Therapeutics in India: rules, payment and research

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2] ClinicalTrials.gov lists 69 studies on Lung Cancer Therapeutics that are recruiting, active or about to start in India.⁠[3]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lung Cancer Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Lung Cancer Therapeutics right now, from free public sources.

Clinical trials

69 active trials in India

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. AstraZeneca 79 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Merck & Co., Inc. 31 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sichuan Baili Pharmaceutical Co., Ltd. 22 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Bristol-Myers Squibb 19 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Johnson & Johnson 17 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Lung Cancer Therapeutics in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Lung Cancer Therapeutics market in India?
Placeholder estimate: about $781.1 Mn in 2025, rising to about $2.42 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lung Cancer Therapeutics market in India growing?
Placeholder estimate: about 13.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lung Cancer Therapeutics market report cover?
The report splits the market by drug class (Targeted Therapy, Immunotherapy, Chemotherapy, Antibody-Drug Conjugates), type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lung Cancer Therapeutics market?
Key players include Merck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and Johnson & Johnson.
What is driving the Lung Cancer Therapeutics market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
Who regulates Lung Cancer Therapeutics in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How many clinical trials on Lung Cancer Therapeutics are running in India?
69 studies are recruiting, active or about to start in India, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
How much research is published on Lung Cancer Therapeutics?
PubMed lists 50 papers on Lung Cancer Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on oncology and respiratory

See the topic